MedImmune gains FDA approval for infant respiratory drug
The Food and Drug Administration recently approved palivizumab, a genetically engineered drug designed to protect infants - particularly those born prematurely - from respiratory syncytial virus (RSV).
The drug will be marketed in partnership with the Ross Products Division of Abbott Park, IL-based Abbott Laboratories under the brand name Synagis.
Palivizumab can be given like an ordinary shot in a doctor's office, while an earlier drug developed by Bethesda, MD-based MedImmune, RSV Immune Globulin Intravenous, is given as an IV infusion over several hours. Both drugs are given in five monthly doses in order to build up protection against RSV.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content